Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 1 | 2016 | 6 | 0.560 |
Why?
|
| Ophthalmology | 1 | 2016 | 4 | 0.560 |
Why?
|
| Retinopathy of Prematurity | 1 | 2016 | 8 | 0.560 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 77 | 0.530 |
Why?
|
| Retinal Hemorrhage | 2 | 2013 | 13 | 0.420 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2009 | 1 | 0.370 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2009 | 2 | 0.370 |
Why?
|
| Eye Foreign Bodies | 1 | 2009 | 2 | 0.370 |
Why?
|
| Metals | 1 | 2009 | 16 | 0.360 |
Why?
|
| Arachnoid Cysts | 1 | 2008 | 1 | 0.340 |
Why?
|
| Pupil Disorders | 1 | 2008 | 2 | 0.340 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 3 | 0.330 |
Why?
|
| Shaken Baby Syndrome | 1 | 2007 | 4 | 0.300 |
Why?
|
| Oculomotor Muscles | 2 | 2017 | 5 | 0.240 |
Why?
|
| Child Abuse | 2 | 2013 | 26 | 0.190 |
Why?
|
| Gestational Age | 2 | 2016 | 96 | 0.160 |
Why?
|
| Eyelid Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
| Eyelids | 1 | 2017 | 9 | 0.150 |
Why?
|
| Eye Movements | 1 | 2017 | 12 | 0.150 |
Why?
|
| Infant | 3 | 2010 | 973 | 0.140 |
Why?
|
| Procaine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Propoxycaine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Tetracaine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Ataxia Telangiectasia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2016 | 1 | 0.140 |
Why?
|
| Eye Infections, Parasitic | 1 | 2016 | 2 | 0.140 |
Why?
|
| Conjunctival Diseases | 1 | 2016 | 4 | 0.140 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 47 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2016 | 603 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 45 | 0.140 |
Why?
|
| Retinal Diseases | 1 | 2016 | 18 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2016 | 130 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2016 | 177 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2016 | 149 | 0.130 |
Why?
|
| Humans | 9 | 2017 | 29220 | 0.120 |
Why?
|
| Head Injuries, Closed | 1 | 2013 | 17 | 0.120 |
Why?
|
| Child | 4 | 2016 | 2221 | 0.110 |
Why?
|
| Male | 6 | 2016 | 17876 | 0.100 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Amblyopia | 1 | 2010 | 2 | 0.090 |
Why?
|
| Eyeglasses | 1 | 2010 | 3 | 0.090 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2010 | 9 | 0.090 |
Why?
|
| Occlusive Dressings | 1 | 2010 | 10 | 0.090 |
Why?
|
| Sensory Deprivation | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sulfones | 1 | 2010 | 14 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 23 | 0.090 |
Why?
|
| Eye | 1 | 2010 | 15 | 0.090 |
Why?
|
| Eye Protective Devices | 1 | 2009 | 6 | 0.090 |
Why?
|
| Piperazines | 1 | 2010 | 56 | 0.090 |
Why?
|
| Visual Acuity | 1 | 2010 | 66 | 0.090 |
Why?
|
| Recurrence | 1 | 2009 | 235 | 0.090 |
Why?
|
| Ophthalmoplegia | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mydriasis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Parasympathetic Fibers, Postganglionic | 1 | 2008 | 1 | 0.080 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 4 | 0.080 |
Why?
|
| Pilocarpine | 1 | 2008 | 5 | 0.080 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 7 | 0.080 |
Why?
|
| Iris | 1 | 2008 | 6 | 0.080 |
Why?
|
| Cholinergic Fibers | 1 | 2008 | 7 | 0.080 |
Why?
|
| Acetylcholine | 1 | 2008 | 47 | 0.080 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 53 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 98 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 1219 | 0.080 |
Why?
|
| Fathers | 1 | 2007 | 11 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 1 | 2007 | 32 | 0.070 |
Why?
|
| Age Factors | 1 | 2008 | 1110 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2010 | 3108 | 0.060 |
Why?
|
| Female | 4 | 2017 | 18241 | 0.050 |
Why?
|
| Toxoplasma | 1 | 2016 | 2 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 43 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 172 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 42 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.030 |
Why?
|
| Photography | 1 | 2013 | 33 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 871 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 726 | 0.020 |
Why?
|
| Purines | 1 | 2010 | 16 | 0.020 |
Why?
|
| Birth Weight | 1 | 2010 | 39 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 169 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 3265 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 1168 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 1313 | 0.020 |
Why?
|